The French Supreme Court confirms fines imposed on undertaking for abusive limitation of generic entry (Sanofi-Aventis)

On 18 October 2016, the French Supreme Court upheld the decision of the French Competition Authority (“FCA”) which had fined the pharmaceutical company Sanofi-Aventis over € 40 million for having abused its dominant position on the market for the active ingredient clopidogrel. Sanofi-Aventis was found to have conducted a communication campaign denigrating the

Access to this article is restricted to subscribers

Already Subscribed? Sign-in

Access to this article is restricted to subscribers.

Read one article for free

Sign-up to read this article for free and discover our services.

 

PDF Version

Author

  • Van Bael & Bellis (Brussels)

Quotation

Tim Kasten, The French Supreme Court confirms fines imposed on undertaking for abusive limitation of generic entry (Sanofi-Aventis), 18 October 2016, e-Competitions Bulletin Competition in the Pharmaceutical sector, Art. N° 81972

Visites 237

All issues

  • Latest News issue 
  • All News issues
  • Latest Special issue 
  • All Special issues